

| Field Name | Field Description |
|---------------------------------------|---|
| Prior Authorization Group Description | Peanut Allergy Immunotherapy Agents (FDA Approved) |
| Drugs | Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] capsule/sachet |
| Covered Uses | Medically accepted indications are defined using the following sources: the Food and Drug Administration (FDA), Micromedex, American Hospital Formulary Service (AHFS), United States Pharmacopeia Drug Information for the Healthcare Professional (USP DI), the Drug Package Insert (PPI), or disease state specific standard of care guidelines. |
| Exclusion Criteria | N/A |
| Required Medical Information | See “Other Criteria” |
| Age Restrictions | Initiation: Patient is age 4-17 years. Up dosing and maintenance: Patient is age ≥ 4 years |
| Prescriber Restrictions | Prescriber is a specialist in the area of allergy/immunology |
| Coverage Duration | 6 months |
| Other Criteria | <p><u>Initial Authorization:</u> Palforzia is approved when all of the following criteria are met:</p> <ul style="list-style-type: none"> • Patient has a confirmed diagnosis of peanut allergy • For patients starting initial dose escalation (new to therapy) <ul style="list-style-type: none"> ○ Patient has not had severe or life-threatening anaphylaxis within the previous 60 days • Patient will follow a peanut-avoidant diet • Patient has been prescribed and has acquired (as demonstrated by pharmacy claims or documentation) injectable epinephrine • No history of eosinophilic esophagitis or other eosinophilic gastrointestinal disease • Patient does not have uncontrolled asthma <p><u>Criteria for Re-Authorization:</u> Palforzia is approved for re-authorization when all of the following criteria are met</p> <ul style="list-style-type: none"> • Patient will follow a peanut-avoidant diet • Patient is able to tolerate at least the 3 mg dose daily • Patient is able to comply with the daily dosing requirements • Patient does not have recurrent asthma exacerbations or persistent loss of asthma control • Patient has been prescribed and has acquired (as demonstrated by pharmacy claims or documentation) injectable epinephrine |

| | |
|--------------------------------|--|
| Revision/Review Date 4/2023 | Medical Director/clinical reviewer must override criteria when, in his/her professional judgement, the requested item is medically necessary. |
|--------------------------------|--|